Sanofi India Share Price
Sector: Biotechnology & Drugs
6060.55 -217.90 (-3.47%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6046.95
Today’s High
6224.00
52 Week Low
4145.90
52 Week High
7593.60
6064.00 -209.00 (-3.33%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6048.00
Today’s High
6232.00
52 Week Low
4861.23
52 Week High
7600.00
Key Metrics
- Market Cap (In Cr) 13957.45
- Beta 0.6
- Div. Yield (%) 1.87
- P/B 16.79
- TTM P/E 44.95
- Peg Ratio -1.14
- Sector P/E 26.62
- D/E 0
- Open Price 6200.05
- Prev Close 6278.45
Sanofi India Analysis
Price Analysis
-
1 Week0.83%
-
3 Months17.59%
-
6 Month-1.55%
-
YTD2.46%
-
1 Year23.01%
Risk Meter
- 25% Low risk
- 25% Moderate risk
- 25% Balanced Risk
- 25% High risk
- 25% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 2
- 2
- 2
- 2
Sanofi India News
Muthoot, Sanofi India to trade ex-dividend today; Ami Organics to trade ex split
2 min read . 25 Apr 2025Stocks to watch: TCS, Bharti Hexacom, Infosys, BHEL among shares in focus today
3 min read . 11 Apr 2025Top stock picks by market experts: Recommended stocks to buy on 8 April
4 min read . 08 Apr 2025Sanofi India share price rises up to 6% post Q4 results, Dividend announcements
1 min read . 28 Feb 2025Sanofi India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 2013.2
- Selling/ General/ Admin Expenses Total
- 525.5
- Depreciation/ Amortization
- 36.7
- Other Operating Expenses Total
- -0.2
- Total Operating Expense
- 1597.1
- Operating Income
- 416.1
- Net Income Before Taxes
- 431.4
- Net Income
- 413.3
- Diluted Normalized EPS
- 147.96
- Period
- 2024
- Total Assets
- 1611.8
- Total Liabilities
- 751.2
- Total Equity
- 860.6
- Tangible Book Valueper Share Common Eq
- 373.11
- Period
- 2024
- Cashfrom Operating Activities
- 300.9
- Cashfrom Investing Activities
- -19.2
- Cashfrom Financing Activities
- -392.4
- Net Changein Cash
- -110.7
- Period
- 2023
- Total Revenue
- 1996.1
- Selling/ General/ Admin Expenses Total
- 538.8
- Depreciation/ Amortization
- 36.5
- Other Operating Expenses Total
- -0.2
- Total Operating Expense
- 1549
- Operating Income
- 447.1
- Net Income Before Taxes
- 528.5
- Net Income
- 602.9
- Diluted Normalized EPS
- 153.22
- Period
- 2023
- Total Assets
- 1714.8
- Total Liabilities
- 699.6
- Total Equity
- 1015.2
- Tangible Book Valueper Share Common Eq
- 437.55
- Period
- 2023
- Cashfrom Operating Activities
- 230.4
- Cashfrom Investing Activities
- 37.5
- Cashfrom Financing Activities
- -878.3
- Net Changein Cash
- -610.4
- Period
- 2022
- Total Revenue
- 2770.1
- Selling/ General/ Admin Expenses Total
- 850.2
- Depreciation/ Amortization
- 41.9
- Other Operating Expenses Total
- -0.2
- Total Operating Expense
- 1989.1
- Operating Income
- 781
- Net Income Before Taxes
- 864.3
- Net Income
- 620.6
- Diluted Normalized EPS
- 229.28
- Period
- 2022
- Total Assets
- 2071.7
- Total Liabilities
- 795.9
- Total Equity
- 1275.8
- Tangible Book Valueper Share Common Eq
- 551.74
- Period
- 2022
- Cashfrom Operating Activities
- 398.7
- Cashfrom Investing Activities
- 650.9
- Cashfrom Financing Activities
- -1582.7
- Net Changein Cash
- -533.1
- Period
- 2021
- Total Revenue
- 2956.6
- Selling/ General/ Admin Expenses Total
- 862.8
- Depreciation/ Amortization
- 66.7
- Other Operating Expenses Total
- -0.1
- Total Operating Expense
- 1771.5
- Operating Income
- 1185.1
- Net Income Before Taxes
- 1257.6
- Net Income
- 944.4
- Diluted Normalized EPS
- 248.4
- Period
- 2021
- Total Assets
- 3061
- Total Liabilities
- 835.4
- Total Equity
- 2225.6
- Tangible Book Valueper Share Common Eq
- 964.11
- Period
- 2021
- Cashfrom Operating Activities
- 558.8
- Cashfrom Investing Activities
- 630.8
- Cashfrom Financing Activities
- -849
- Net Changein Cash
- 340.6
- Period
- 2020
- Total Revenue
- 2901.9
- Selling/ General/ Admin Expenses Total
- 894.4
- Depreciation/ Amortization
- 82.2
- Other Operating Expenses Total
- -0.1
- Total Operating Expense
- 2309.8
- Operating Income
- 592.1
- Net Income Before Taxes
- 677.2
- Net Income
- 477.6
- Diluted Normalized EPS
- 221
- Period
- 2020
- Total Assets
- 2918.5
- Total Liabilities
- 799.5
- Total Equity
- 2119
- Tangible Book Valueper Share Common Eq
- 871.8
- Period
- 2020
- Cashfrom Operating Activities
- 611.1
- Cashfrom Investing Activities
- 276.4
- Cashfrom Financing Activities
- -810
- Net Changein Cash
- 77.5
- Period
- 2019
- Total Revenue
- 3070.6
- Selling/ General/ Admin Expenses Total
- 992
- Depreciation/ Amortization
- 99.9
- Other Operating Expenses Total
- -0.3
- Total Operating Expense
- 2562.3
- Operating Income
- 508.3
- Net Income Before Taxes
- 599.9
- Net Income
- 414.2
- Diluted Normalized EPS
- 198.2
- Period
- 2019
- Total Assets
- 3244.4
- Total Liabilities
- 802.1
- Total Equity
- 2442.3
- Tangible Book Valueper Share Common Eq
- 995.02
- Period
- 2019
- Cashfrom Operating Activities
- 412.3
- Cashfrom Investing Activities
- 65.7
- Cashfrom Financing Activities
- -183.2
- Net Changein Cash
- 294.8
- Period
- 2018
- Total Revenue
- 2770.8
- Selling/ General/ Admin Expenses Total
- 914.9
- Depreciation/ Amortization
- 102.7
- Other Operating Expenses Total
- 22.8
- Total Operating Expense
- 2248.1
- Operating Income
- 522.7
- Net Income Before Taxes
- 609.8
- Net Income
- 380.6
- Diluted Normalized EPS
- 165.75
- Period
- 2018
- Total Assets
- 2983.9
- Total Liabilities
- 764.7
- Total Equity
- 2219.2
- Tangible Book Valueper Share Common Eq
- 881.26
- Period
- 2018
- Cashfrom Operating Activities
- 373.9
- Cashfrom Investing Activities
- -73.1
- Cashfrom Financing Activities
- -197.2
- Net Changein Cash
- 103.6
- Period
- 2024-12-31
- Total Revenue
- 514.9
- Selling/ General/ Admin Expenses Total
- 53.8
- Depreciation/ Amortization
- 9.6
- Other Operating Expenses Total
- 93
- Total Operating Expense
- 406.2
- Operating Income
- 108.7
- Net Income Before Taxes
- 122.2
- Net Income
- 91.3
- Diluted Normalized EPS
- 37.05
- Period
- 2024-12-31
- Total Assets
- 1611.8
- Total Liabilities
- 751.2
- Total Equity
- 860.6
- Tangible Book Valueper Share Common Eq
- 373.11
- Period
- 2024-12-31
- Cashfrom Operating Activities
- 300.9
- Cashfrom Investing Activities
- -19.2
- Cashfrom Financing Activities
- -392.4
- Net Changein Cash
- -110.7
- Period
- 2024-09-30
- Total Revenue
- 524
- Selling/ General/ Admin Expenses Total
- 56.7
- Depreciation/ Amortization
- 9
- Other Operating Expenses Total
- 87.6
- Total Operating Expense
- 413.3
- Operating Income
- 110.7
- Net Income Before Taxes
- 112.6
- Net Income
- 82.2
- Diluted Normalized EPS
- 35.69
- Period
- 2024-09-30
- Period
- 2024-09-30
- Period
- 2024-06-30
- Total Revenue
- 463.5
- Selling/ General/ Admin Expenses Total
- 60.2
- Depreciation/ Amortization
- 9
- Other Operating Expenses Total
- 66.5
- Total Operating Expense
- 356.8
- Operating Income
- 106.7
- Net Income Before Taxes
- 92.1
- Net Income
- 103.2
- Diluted Normalized EPS
- 35.72
- Period
- 2024-06-30
- Total Assets
- 1360.3
- Total Liabilities
- 675.7
- Total Equity
- 684.6
- Tangible Book Valueper Share Common Eq
- 296.56
- Period
- 2024-06-30
- Cashfrom Operating Activities
- 254.1
- Cashfrom Investing Activities
- -12.1
- Cashfrom Financing Activities
- -388.3
- Net Changein Cash
- -146.3
- Period
- 2024-03-31
- Total Revenue
- 510.8
- Selling/ General/ Admin Expenses Total
- 69.5
- Depreciation/ Amortization
- 9.1
- Other Operating Expenses Total
- 55.8
- Total Operating Expense
- 382.8
- Operating Income
- 128
- Net Income Before Taxes
- 104.5
- Net Income
- 136.6
- Diluted Normalized EPS
- 39.25
- Period
- 2024-03-31
- Period
- 2024-03-31
- Period
- 2023-12-31
- Total Revenue
- 469.2
- Selling/ General/ Admin Expenses Total
- 72.5
- Depreciation/ Amortization
- 9.3
- Other Operating Expenses Total
- 77.7
- Total Operating Expense
- 378.9
- Operating Income
- 90.3
- Net Income Before Taxes
- 99.3
- Net Income
- 137.7
- Diluted Normalized EPS
- 30.26
- Period
- 2023-12-31
- Total Assets
- 1714.8
- Total Liabilities
- 699.6
- Total Equity
- 1015.2
- Tangible Book Valueper Share Common Eq
- 437.55
- Period
- 2023-12-31
- Cashfrom Operating Activities
- 230.4
- Cashfrom Investing Activities
- 37.5
- Cashfrom Financing Activities
- -878.3
- Net Changein Cash
- -610.4
- Period
- 2023-09-30
- Total Revenue
- 490.7
- Selling/ General/ Admin Expenses Total
- 71.5
- Depreciation/ Amortization
- 9.2
- Other Operating Expenses Total
- 66.6
- Total Operating Expense
- 386.4
- Operating Income
- 104.3
- Net Income Before Taxes
- 114.6
- Net Income
- 151.9
- Diluted Normalized EPS
- 34.99
- Period
- 2023-09-30
- Period
- 2023-09-30
- Period
- 2023-06-30
- Total Revenue
- 706.1
- Selling/ General/ Admin Expenses Total
- 93.7
- Depreciation/ Amortization
- 9.8
- Other Operating Expenses Total
- 117.9
- Total Operating Expense
- 537.7
- Operating Income
- 168.4
- Net Income Before Taxes
- 183.4
- Net Income
- 122.9
- Diluted Normalized EPS
- 53.37
- Period
- 2023-06-30
- Total Assets
- 1497.6
- Total Liabilities
- 773.4
- Total Equity
- 724.2
- Tangible Book Valueper Share Common Eq
- 311.45
- Period
- 2023-06-30
- Cashfrom Operating Activities
- 259.3
- Cashfrom Investing Activities
- 43.4
- Cashfrom Financing Activities
- -873.5
- Net Changein Cash
- -570.8
- Period
- 2023-03-31
- Total Revenue
- 736.5
- Selling/ General/ Admin Expenses Total
- 91.8
- Depreciation/ Amortization
- 9.7
- Other Operating Expenses Total
- 110.2
- Total Operating Expense
- 516.3
- Operating Income
- 220.2
- Net Income Before Taxes
- 263.5
- Net Income
- 190.4
- Diluted Normalized EPS
- 77.09
- Period
- 2023-03-31
- Period
- 2023-03-31
- Period
- 2022-12-31
- Total Revenue
- 671.9
- Selling/ General/ Admin Expenses Total
- 103.6
- Depreciation/ Amortization
- 10
- Other Operating Expenses Total
- 120.3
- Total Operating Expense
- 501.1
- Operating Income
- 170.8
- Net Income Before Taxes
- 190.4
- Net Income
- 130.9
- Diluted Normalized EPS
- 52.69
- Period
- 2022-12-31
- Total Assets
- 2071.7
- Total Liabilities
- 795.9
- Total Equity
- 1275.8
- Tangible Book Valueper Share Common Eq
- 551.74
- Period
- 2022-12-31
- Cashfrom Operating Activities
- 398.7
- Cashfrom Investing Activities
- 650.9
- Cashfrom Financing Activities
- -1582.7
- Net Changein Cash
- -533.1
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Sanofi India Technical
Moving Average
SMA
- 5 Day6391.13
- 10 Day6281.29
- 20 Day6115.89
- 50 Day5673.88
- 100 Day5773.44
- 300 Day6244.79
Sanofi India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Alembic Pharmaceuticals
- 872.95
- -2.5
- -0.29
- 1296.15
- 725.6
- 17070.26
- Natco Pharma
- 885
- -4.65
- -0.52
- 1638.35
- 660.05
- 15851.22
- Sanofi India
- 6060.55
- -217.9
- -3.47
- 7593.6
- 4145.9
- 13957.45
- Jubilant Pharmova
- 907.05
- -3.65
- -0.4
- 1309
- 616.85
- 14447.59
- Caplin Point Laboratories
- 1909.3
- 103.3
- 5.72
- 2636
- 1221
- 14404.83
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Alembic Pharmaceuticals
- 28.02
- 3.57
- 15.94
- 12.47
- Natco Pharma
- 11.49
- 2.72
- 14.63
- 25.16
- Sanofi India
- 42.4
- 16.79
- 32.83
- 21.53
- Jubilant Pharmova
- 96.94
- 2.65
- 6.15
- 5.13
- Caplin Point Laboratories
- 30.13
- 5.92
- 22.81
- 25.39
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 27-Feb-25
- Audited Results & Final Dividend
- 07-Nov-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 13-May-24
- Quarterly Results
- 23-Feb-24
- Audited Results & Dividend
- 08-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 10-May-23
- Quarterly Results
- 23-Feb-23
- Audited Results & Dividend
- 03-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 15-May-25
- 23-Apr-25
- AGM
- 10-Aug-24
- 11-Jul-24
- POM
- 14-May-24
- 22-Apr-24
- AGM
- 15-Feb-24
- 12-Jan-24
- POM
- 18-Dec-23
- 13-Nov-23
- COM
- 07-Nov-23
- 03-Oct-23
- POM
- 11-May-23
- 23-Feb-23
- AGM
- 24-Jun-22
- 28-Apr-22
- POM
- 26-Apr-22
- 23-Feb-22
- AGM
- 25-Mar-22
- 15-Feb-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-Feb-25
- 25-Apr-25
- 25-Apr-25
- 117
- 24-Feb-24
- 03-May-24
- 03-May-24
- 117
- 23-Feb-24
- 07-Mar-24
- 07-Mar-24
- 50
- 23-Feb-23
- -
- 28-Apr-23
- 194
- 24-Feb-23
- -
- 28-Apr-23
- 183
- 13-Jul-22
- 08-Aug-22
- 05-Aug-22
- 0
- 13-Jul-22
- 08-Aug-22
- 05-Aug-22
- 193
- 24-Feb-22
- -
- 12-Apr-22
- 309
- 23-Feb-22
- -
- 12-Apr-22
- 181
- 23-Feb-21
- -
- 19-Apr-21
- 125


